Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The Investigators in the PCRT team have developed a therapeutic regimen which attacks both
the tumor compartment and the stromal compartment of pancreatic cancer and induces complete
responses in a small percentage of patients with advanced stage IV pancreatic cancer.